{
 "drug": "Liraglutide Injection",
 "asOf": "2026-08-25",
 "status": "in-shortage",
 "since": "07/18/2023",
 "dayN": 1134,
 "cat": "Endocrinology/Metabolism",
 "companies": [
  "Hikma Pharmaceuticals USA, Inc.",
  "Teva Pharmaceuticals USA, Inc.",
  "Novo Nordisk, Inc.",
  "Meitheal Pharmaceuticals, Inc."
 ],
 "reasons": [
  "Delay in shipping of the drug",
  "Other"
 ],
 "records": [
  {
   "update_type": "Reverified",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "0143-9144-03",
   "generic_name": "Liraglutide Injection",
   "contact_info": "800-631-2174",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "ANDA215503"
    ],
    "brand_name": [
     "LIRAGLUTIDE"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Hikma Pharmaceuticals USA Inc."
    ],
    "product_ndc": [
     "0143-9144"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "897122"
    ],
    "spl_id": [
     "4e2acb7a-d32d-49d3-b59b-39332b5809f3"
    ],
    "spl_set_id": [
     "2100ec49-57b2-4330-ab5f-057ce9b7e4d0"
    ],
    "package_ndc": [
     "0143-9144-01",
     "0143-9144-03",
     "0143-9144-02"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "08/13/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)",
   "company_name": "Hikma Pharmaceuticals USA, Inc.",
   "status": "Current"
  },
  {
   "discontinued_date": "05/14/2026",
   "update_type": "New",
   "initial_posting_date": "05/14/2026",
   "package_ndc": "0480-7250-46",
   "generic_name": "Liraglutide Injection",
   "contact_info": "888-838-2872",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "ANDA214568"
    ],
    "brand_name": [
     "LIRAGLUTIDE"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Teva Pharmaceuticals, Inc."
    ],
    "product_ndc": [
     "0480-7250"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "2735350"
    ],
    "spl_id": [
     "4df44cd9-cb11-46b6-ba6c-88ff963ec414"
    ],
    "spl_set_id": [
     "625ac780-70a9-41e4-a892-bcba0f803f1c"
    ],
    "package_ndc": [
     "0480-7250-46"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "05/14/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "status": "To Be Discontinued"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "0480-3667-22",
   "generic_name": "Liraglutide Injection",
   "contact_info": "833-493-4689",
   "availability": "Available",
   "related_info": "Distributed by Teva",
   "openfda": {
    "application_number": [
     "NDA022341"
    ],
    "brand_name": [
     "LIRAGLUTIDE"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Teva Pharmaceuticals USA, Inc."
    ],
    "product_ndc": [
     "0480-3667"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "897122"
    ],
    "spl_id": [
     "57c9f463-a1b8-4efa-8982-40175cf6cf4f"
    ],
    "spl_set_id": [
     "14bf9812-14ee-46ce-93b1-686e4906cbbc"
    ],
    "package_ndc": [
     "0480-3667-19",
     "0480-3667-22",
     "0480-3667-20"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)",
   "company_name": "Novo Nordisk, Inc.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "0169-4060-12",
   "generic_name": "Liraglutide Injection",
   "contact_info": "833-493-4689",
   "availability": "Limited Availability",
   "related_info": "Estimated shortage duration TBD",
   "openfda": {
    "application_number": [
     "NDA022341"
    ],
    "brand_name": [
     "VICTOZA"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Novo Nordisk"
    ],
    "product_ndc": [
     "0169-4060"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "897122",
     "897126"
    ],
    "spl_id": [
     "0d10d10e-0fe0-47ee-b9da-628e34907e98"
    ],
    "spl_set_id": [
     "5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"
    ],
    "package_ndc": [
     "0169-4060-13",
     "0169-4060-12",
     "0169-4060-90",
     "0169-4060-97",
     "0169-4060-98",
     "0169-4060-99"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)",
   "company_name": "Novo Nordisk, Inc.",
   "shortage_reason": "Delay in shipping of the drug",
   "status": "Current"
  },
  {
   "update_type": "Revised",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "71288-563-85",
   "generic_name": "Liraglutide Injection",
   "contact_info": "844-824-8426",
   "availability": "Limited Availability",
   "related_info": "Estimated recovery: July 2026",
   "openfda": {
    "application_number": [
     "ANDA218115"
    ],
    "brand_name": [
     "LIRAGLUTIDE"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Meitheal Pharmaceuticals Inc."
    ],
    "product_ndc": [
     "71288-563"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "897122"
    ],
    "spl_id": [
     "a0bb0116-f90a-490b-9ca9-5bcd6210c763"
    ],
    "spl_set_id": [
     "0efc3a89-211a-4496-baab-e8265e07de2b"
    ],
    "package_ndc": [
     "71288-563-84",
     "71288-563-85"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "06/01/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)",
   "company_name": "Meitheal Pharmaceuticals, Inc.",
   "shortage_reason": "Other",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "0143-9144-02",
   "generic_name": "Liraglutide Injection",
   "contact_info": "800-631-2174",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "ANDA215503"
    ],
    "brand_name": [
     "LIRAGLUTIDE"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Hikma Pharmaceuticals USA Inc."
    ],
    "product_ndc": [
     "0143-9144"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "897122"
    ],
    "spl_id": [
     "4e2acb7a-d32d-49d3-b59b-39332b5809f3"
    ],
    "spl_set_id": [
     "2100ec49-57b2-4330-ab5f-057ce9b7e4d0"
    ],
    "package_ndc": [
     "0143-9144-01",
     "0143-9144-03",
     "0143-9144-02"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "08/13/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)",
   "company_name": "Hikma Pharmaceuticals USA, Inc.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "0169-4060-13",
   "generic_name": "Liraglutide Injection",
   "contact_info": "833-493-4689",
   "availability": "Limited Availability",
   "related_info": "Estimated shortage duration TBD",
   "openfda": {
    "application_number": [
     "NDA022341"
    ],
    "brand_name": [
     "VICTOZA"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Novo Nordisk"
    ],
    "product_ndc": [
     "0169-4060"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "897122",
     "897126"
    ],
    "spl_id": [
     "0d10d10e-0fe0-47ee-b9da-628e34907e98"
    ],
    "spl_set_id": [
     "5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"
    ],
    "package_ndc": [
     "0169-4060-13",
     "0169-4060-12",
     "0169-4060-90",
     "0169-4060-97",
     "0169-4060-98",
     "0169-4060-99"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)",
   "company_name": "Novo Nordisk, Inc.",
   "shortage_reason": "Delay in shipping of the drug",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "71288-563-84",
   "generic_name": "Liraglutide Injection",
   "contact_info": "844-824-8426",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "ANDA218115"
    ],
    "brand_name": [
     "LIRAGLUTIDE"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Meitheal Pharmaceuticals Inc."
    ],
    "product_ndc": [
     "71288-563"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "897122"
    ],
    "spl_id": [
     "a0bb0116-f90a-490b-9ca9-5bcd6210c763"
    ],
    "spl_set_id": [
     "0efc3a89-211a-4496-baab-e8265e07de2b"
    ],
    "package_ndc": [
     "71288-563-84",
     "71288-563-85"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "06/01/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)",
   "company_name": "Meitheal Pharmaceuticals, Inc.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "0480-3667-20",
   "generic_name": "Liraglutide Injection",
   "contact_info": "833-493-4689",
   "availability": "Available",
   "related_info": "Distributed by Teva",
   "openfda": {
    "application_number": [
     "NDA022341"
    ],
    "brand_name": [
     "LIRAGLUTIDE"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Teva Pharmaceuticals USA, Inc."
    ],
    "product_ndc": [
     "0480-3667"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "897122"
    ],
    "spl_id": [
     "57c9f463-a1b8-4efa-8982-40175cf6cf4f"
    ],
    "spl_set_id": [
     "14bf9812-14ee-46ce-93b1-686e4906cbbc"
    ],
    "package_ndc": [
     "0480-3667-19",
     "0480-3667-22",
     "0480-3667-20"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)",
   "company_name": "Novo Nordisk, Inc.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "07/18/2023",
   "package_ndc": "0169-2800-15",
   "generic_name": "Liraglutide Injection",
   "contact_info": "833-493-4689",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "NDA206321"
    ],
    "brand_name": [
     "SAXENDA"
    ],
    "generic_name": [
     "LIRAGLUTIDE"
    ],
    "manufacturer_name": [
     "Novo Nordisk Pharmaceutical Industries, LP"
    ],
    "product_ndc": [
     "0169-2800"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "LIRAGLUTIDE"
    ],
    "rxcui": [
     "1598268",
     "2735350"
    ],
    "spl_id": [
     "7e183945-550d-4b6a-bf4e-300193517cac"
    ],
    "spl_set_id": [
     "3946d389-0926-4f77-a708-0acb8153b143"
    ],
    "package_ndc": [
     "0169-2800-15",
     "0169-2800-90",
     "0169-2800-97"
    ],
    "nui": [
     "N0000178480",
     "M0160181",
     "N0000020058"
    ],
    "pharm_class_epc": [
     "GLP-1 Receptor Agonist [EPC]"
    ],
    "pharm_class_cs": [
     "Glucagon-Like Peptide 1 [CS]"
    ],
    "pharm_class_moa": [
     "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
    ],
    "unii": [
     "839I73S42A"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Endocrinology/Metabolism"
   ],
   "dosage_form": "Injection",
   "presentation": "Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)",
   "company_name": "Novo Nordisk, Inc.",
   "status": "Current"
  }
 ]
}